Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro - PubMed (original) (raw)

Review

Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro

H E Scharfman et al. Amino Acids. 2000.

Abstract

In this review, recent studies on the electrophysiological effects of de novo synthesized ("endogenous") kynurenic acid (KYNA) are discussed. Endogenous KYNA is normally formed as a byproduct of tryptophan metabolism. Evidence for a physiological role in neuronal excitability has not been strong, in part because brain levels are much lower than the KD of KYNA at the glycine site of the NMDA receptor, where KYNA is thought to exert its most potent effect. The results suggest that, unexpectedly, even low concentrations of endogenous KYNA have physiological consequences. These levels of KYNA reduced the number of hippocampal slices with spontaneous epileptiform discharges after exposure to buffer lacking magnesium. However, effects on evoked responses to single afferent stimuli were not detected. Taken together, the data argue for a potentially important role of endogenous KYNA in suppression of seizure-like activity, and suggest a novel approach to anticonvulsant drug development that could have few side effects.

PubMed Disclaimer

Similar articles

• Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices.
  Scharfman HE, Hodgkins PS, Lee SC, Schwarcz R. Scharfman HE, et al. Neurosci Lett. 1999 Oct 22;274(2):111-4. doi: 10.1016/s0304-3940(99)00690-4. Neurosci Lett. 1999. PMID: 10553950
• The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.
  Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. Hilmas C, et al. J Neurosci. 2001 Oct 1;21(19):7463-73. doi: 10.1523/JNEUROSCI.21-19-07463.2001. J Neurosci. 2001. PMID: 11567036 Free PMC article.
• Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels.
  Mok MH, Fricker AC, Weil A, Kew JN. Mok MH, et al. Neuropharmacology. 2009 Sep;57(3):242-9. doi: 10.1016/j.neuropharm.2009.06.003. Epub 2009 Jun 11. Neuropharmacology. 2009. PMID: 19523966
• Kynurenic acid and cancer: facts and controversies.
  Walczak K, Wnorowski A, Turski WA, Plech T. Walczak K, et al. Cell Mol Life Sci. 2020 Apr;77(8):1531-1550. doi: 10.1007/s00018-019-03332-w. Epub 2019 Oct 28. Cell Mol Life Sci. 2020. PMID: 31659416 Free PMC article. Review.
• Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery.
  Moroni F, Cozzi A, Sili M, Mannaioni G. Moroni F, et al. J Neural Transm (Vienna). 2012 Feb;119(2):133-9. doi: 10.1007/s00702-011-0763-x. Epub 2012 Jan 4. J Neural Transm (Vienna). 2012. PMID: 22215208 Review.

Cited by

• Kynurenine pathway metabolites in humans: disease and healthy States.
  Chen Y, Guillemin GJ. Chen Y, et al. Int J Tryptophan Res. 2009;2:1-19. doi: 10.4137/ijtr.s2097. Epub 2009 Jan 8. Int J Tryptophan Res. 2009. PMID: 22084578 Free PMC article.
• Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.
  Wonodi I, McMahon RP, Krishna N, Mitchell BD, Liu J, Glassman M, Hong LE, Gold JM. Wonodi I, et al. Schizophr Res. 2014 Dec;160(1-3):80-7. doi: 10.1016/j.schres.2014.10.026. Epub 2014 Nov 14. Schizophr Res. 2014. PMID: 25464917 Free PMC article.
• Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons.
  Dobelis P, Staley KJ, Cooper DC. Dobelis P, et al. PLoS One. 2012;7(7):e41108. doi: 10.1371/journal.pone.0041108. Epub 2012 Jul 25. PLoS One. 2012. PMID: 22848433 Free PMC article.
• The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex.
  McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG. McTighe SM, et al. PLoS One. 2013 Apr 24;8(4):e62189. doi: 10.1371/journal.pone.0062189. Print 2013. PLoS One. 2013. PMID: 23638000 Free PMC article.
• Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
  Bai MY, Lovejoy DB, Guillemin GJ, Kozak R, Stone TW, Koola MM. Bai MY, et al. Complex Psychiatry. 2021 Aug;7(1-2):19-33. doi: 10.1159/000515066. Epub 2021 Feb 8. Complex Psychiatry. 2021. PMID: 35141700 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer